Date: 2026-02-22 Quarter: Q4 FY25 (Dec-25) Prior analyses: None — establishing first baseline Atlas baseline: 4/5 conviction, undervalued at 5.6x TTM rev
Q4 FY25: $170.7M revenue (+46% YoY), 85% GM [Non-GAAP], 28% OpM [Non-GAAP], $0.49 non-GAAP EPS (vs $0.14 consensus — 250% beat), $61.5M FCF (36% margin). Rule of 40: 82 !!
FY25 full year: $587.9M (+51% YoY). Non-GAAP operating income $117M (from near-zero in FY24). FCF $179.6M. Rule of 40: 81.
This is an exceptional result. Not just the beat — the character of the beat.
Here's the thing about Hinge Health that most people are missing through the financial lens alone.
The annual yield metric is the NRR signal.
Traditional SaaS has NRR. Hinge Health has annual yield: 3.4% → 3.9% YoY (and first-year 2025 cohorts coming in at 3.3% vs historical 1.3-2.5%). This is the utilization rate of contracted eligible lives. Revenue = contracted lives × yield × revenue per member. When yield expands, you get embedded revenue growth inside existing contracts without adding a single new client.
| Metric | FY23 | FY24 | FY25 | YoY |
|---|---|---|---|---|
| Avg Eligible Lives (M) | 12.2 | 15.7 | 20.1 | +28% |
| Annual Yield | ~n/a | 3.4% | 3.9% | +50bps |
| Members | 370,526 | 532,326 | 782,890 | +47% |
| Contracted Lives (M) | n/a | 20.0 | 24.6 | +24% |
Eligible lives growing 28% per year, yield expanding, NDR >110% [Non-GAAP]. This is a compounding platform effect inside existing relationships — not a new client story.
Crowdsourced intelligence flywheel:
782K members → engagement data → Robin AI improving → better outcomes → 21 peer-reviewed studies → clinical credibility → win more enterprise deals → more members → more data. This is the flywheel I look for. "Crowdsourced intelligence" over "islands of data." Hinge's population-level dataset is increasingly unrivaled. Sword Health has 10M contracted lives but fewer published studies (5-7 vs 21). The evidence base IS the moat.
Building block assessment:
This is closer to a "building block" than a "process tool." Employers embed Hinge into their benefit stack. Once in, members use it repeatedly. Yield expands year over year (330% first-year cohort vs 130-250% historically). The product compounds inside the customer — that's a building block characteristic.
GTM: self-serve or SI-dependent?
Hinge sells direct to large employers through benefits brokers (not SIs). Enterprise sales, but no heavy SI dependency. Win rate at all-time high. Displaced a large competitor with 200K+ lives in December 2024 — that's competitive displacement in an entrenched market, not just greenfield. This is encouraging.
| | Q123 | Q223 | Q323 | Q423 | Q124 | Q224 | Q324 | Q424 | Q125 | Q225 | Q325 | Q425 | | | Mar-23 | Jun-23 | Sep-23 | Dec-23 | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---|---|---|---|---|---|---|---| | Revenue ($m) | 60.0 | 69.8 | 81.4 | 81.5 | 82.7 | 89.8 | 100.6 | 117.3 | 123.8 | 139.1 | 154.2 | 170.7 | | YoY % | — | — | — | — | 37.8% | 28.7% | 23.6% | 43.9% | 49.7% | 54.9% | 53.3% | 45.5% | | GM % [Non-GAAP] | 62% | 68% | 73% | 75% | 71% | 77% | 79% | 82% | 81% | 83% | 83% | 85% | | OpM % [Non-GAAP] | -61% | -47% | -34% | -36% | -16% | -4% | -4% | 18% | 12% | 19% | 20% | 28% | | FCF ($m) | — | — | — | — | — | — | 25.0 | 37.3 | 23.0 | 14.0 | 81.0 | 61.5 | | Non-GAAP EPS | — | — | — | — | — | — | — | $0.40 | — | $0.28 | $0.32 | $0.49 |
GM trajectory: 62% → 68% → 73% → 75% → 71% → 77% → 79% → 82% → 81% → 83% → 83% → 85% !! Relentless expansion. Robin AI is doing the work — 47% more members served with flat care team costs.
OpM trajectory: -61% → -47% → -34% → -36% → -16% → -4% → -4% → 18% → 12% → 19% → 20% → 28% ^^ This is the most impressive operating leverage ramp I've seen outside pure software. From -61% to +28% in 8 quarters.
Non-GAAP EPS: $0.28 → $0.32 → $0.49 ^^ Accelerating nicely.
| Indicator | Q324 | Q424 | Q125 | Q225 | Q325 | Q425 | Trend |
|---|---|---|---|---|---|---|---|
| TTM Billings ($m) | 416.9 | 467.5 | — | 568.4 | 624.2 | 671.4 | Accelerating ^^ |
| Clients | 2,047 | 2,256 | — | 2,359 | 2,560 | 2,830 | Accelerating ^^ |
| Contracted Lives (M) | — | 20.0 | — | — | — | 24.6 | +24% YoY |
| Members | — | 532,326 | — | — | — | 782,890 | +47% YoY |
| NDR | — | — | — | — | — | >110% | First disclosure !! |
| Annual Yield | — | 3.4% | — | — | — | 3.9% | Expanding !! |
NUANCE: The billings-revenue divergence is the key signal here. TTM billings $671M vs TTM revenue $588M = 1.14x ratio. Billings lead revenue by 3-6 months. FY26 guide at $737M mid (25% growth) looks very conservative. Real billings trajectory suggests 35-40% actual growth is achievable — the guide is management building optionality to beat.
Client additions accelerated: ~200/quarter average → +270 in Q4 FY25. That's NOT what you see in a decelerating business.
"We served 47% more members in 2025 while holding care team costs flat."
DING DING DING. That's the operating leverage sentence of the year. Robin AI is doing real work — not just a chatbot.
"Our competitive win rate reached an all-time high."
This directly contradicts the "Sword is catching up" narrative. Management said it, and they backed it with the 200K+ lives displacement.
"First-year cohort members are engaging at a 3.3% yield, compared to the historical range of 1.3% to 2.5%."
The product is improving faster than the historical base. This is the signal that future yield expansion has legs.
"Non-ASO contracted lives grew 130% year-over-year to 2.6 million."
Medicare Advantage + Federal Employee Program. This is embryonic but if it inflects it's a completely new TAM at multiples of the employer market.
1. The yield metric is being underanalyzed by the market.
Annual yield 3.9% means: of 24.6M contracted eligible lives, 782K are active members. First-year cohort yield of 3.3% (vs historical 1.3-2.5%) means the 2025 vintage will likely yield more lifetime revenue than older cohorts. As the yield cohorts compound, embedded revenue growth accelerates without new client adds. This is fundamentally different from traditional SaaS — it's more like a marketplace or platform that deepens utilization over time.
2. The deceleration is real — but so is the sandbagging.
FY25: 51% growth. FY26 guide: 25%. That's a 26pp step-down in guided growth. Even if actual comes in at 35%, the narrative shifts from hypergrowth to "just" fast growth. This is a legitimate risk. My read: billings at $671M TTM growing 44%, client additions accelerating, non-ASO at 130% growth — the real FY26 number is probably 32-38%. But below 30% would be a genuine deceleration story and I'd need to reassess.
3. HingeSelect is a moat deepener, not just a product.
The provider network connecting digital care to in-person PT across 100+ metros is strategic infrastructure. 85% of members adopting conservative care (avoiding surgery) means Hinge is demonstrating ROI to employers in the most measurable way possible. Every surgical avoidance is a $30-50K saving for the employer. This makes Hinge sticky in a way pure software rarely achieves.
4. GAAP profitability is real (post-IPO noise aside).
Q4 FY25 GAAP net income: 32.1M.TheQ2FY25GAAPlossof−679.8M was IPO-related SBC charges. The underlying GAAP trajectory is solidly positive: Q4 FY24 +27.1M → Q3FY25−1.8M (transition) → Q4 FY25 +$32.1M. Management guided continued GAAP profitability for FY26. This is best-of-breed profitability for a company still growing 45%+.
Tier: Tier 2 (high end) — 45.5% Q4 YoY, 51% FY25, guided 25% FY26 (real likely 32-38%). Position allocation: 7.4% of portfolio is appropriate for high-Tier-2 with Tier 1 optionality.
If Q1 FY26 comes in at or above $180M (guide is $171-173M), I would consider upgrading to Tier 1 and adding.
First muji analysis of HNGE — no prior beliefs to compare against. Establishing baseline.
Key things I'm watching:
Hold at 7.4% (current portfolio weight). Add if Q1 FY26 beats guide and yield/billings signals hold.
HNGE is a best-of-breed digital health platform with AI-driven operating leverage that's structural (not cyclical), a moat that compounds via population-level clinical data, and a valuation that remains compelling at ~5.6x TTM revenue. The FY26 guide is sandbagged — the billings-revenue divergence and accelerating client adds tell me that.
The deceleration from 51% to guided 25% requires monitoring. If real growth lands 32-38%, this is a Tier 2 compounder that deserves 7-10% allocation. If growth decelerates below 30%, I reassess.
Not adding aggressively yet because: (1) this is only our third quarter of post-IPO data, (2) the guide implies deceleration, (3) want to confirm non-ASO economics. But thesis is solidly intact.
long HNGE 7.4%
-muji